Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REPLIGEN CORPORATION

(RGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Repligen Corporation : The revival in interest should continue

07/28/2021 | 02:29am EST
long trade
Target price hit
Entry price : 226.26$ | Target : 280$ | Stop-loss : 190$ | Potential : 23.75%
Shares in Repligen Corporation have recently benefitted from a regain of interest by market participants. The technical chart pattern suggests a continuation of the upward movement.
Investors have an opportunity to buy the stock and target the $ 280.
Repligen Corporation : Repligen Corporation : The revival in interest should continue
Summary
  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths
  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The company returns high margins, thereby supporting business profitability.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • For several months, analysts have been revising their EPS estimates roughly upwards.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 120.61 times its estimated earnings per share for the ongoing year.
  • Based on current prices, the company has particularly high valuation levels.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The company is highly valued given the cash flows generated by its activity.

© MarketScreener.com 2021

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (USD)
Sales 2021 660 M - -
Net income 2021 128 M - -
Net cash 2021 431 M - -
P/E ratio 2021 84,7x
Yield 2021 -
Capitalization 10 493 M 10 493 M -
EV / Sales 2021 15,2x
EV / Sales 2022 12,3x
Nbr of Employees -
Free-Float -
Upcoming event on REPLIGEN CORPORATION
02/24/22
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 189,79 $
Average target price 312,56 $
Spread / Average Target 64,7%
EPS Revisions
Managers and Directors
Tony J. Hunt President, Chief Executive Officer & Director
Jon K. Snodgres Chief Financial Officer
Karen A. Dawes Chairman
Ralf Kuriyel Senior Vice President-Research & Development
James R. Bylund Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
REPLIGEN CORPORATION-30.60%10 493
ABBOTT LABORATORIES-12.02%212 347
MEDTRONIC PLC0.73%140 116
BECTON, DICKINSON AND COMPANY3.37%74 100
HOYA CORPORATION-13.50%47 942
BAXTER INTERNATIONAL INC.0.14%43 040